THYROCARE TECHNOLOGIES LTD.
NSE : THYROCAREBSE : 539871ISIN
CODE : INE594H01019Industry : Hospital & Healthcare ServicesHouse
: MNC
BSE625.703.4 (+0.55 % )
PREV CLOSE (Rs.) 622.30
OPEN PRICE (Rs.) 628.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 268360
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE626.10 3.6 (+0.58 % )
PREV CLOSE(Rs.) 622.50
OPEN PRICE (Rs.) 625.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 626.10 (307 )
VOLUME 881123
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 28-Feb-2024 | Thyrocare Technologies completes acquisition of 100% stake in Think Health | <p style="text-align: justify;">Thyrocare Technologies has completed the acquisition by way purchase of 100% equity shares in Think Health Diagnostic (Think Health) from all the existing shareholders of Think Health on February 27, 2024 and consequently Think Health has become wholly-owned subsidiary company of Thyrocare with effective from February 27, 2024.</p><p style="text-align: justify;">Thyrocare Technologies is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries.</p> |
| 28-Feb-2024 | Thyrocare Technologies jumps on completing acquisition of 100% stake in Think Health | <p style="text-align: justify;">Thyrocare Technologies is currently trading at Rs. 717.15, up by 75.35 points or 11.74% from its previous closing of Rs. 641.80 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 646.00 and has touched a high and low of Rs. 722.00 and Rs. 643.00 respectively. So far 25223 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 722.00 on 28-Jan-2024 and a 52 week low of Rs. 416.00 on 29-Mar-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 722.00 and Rs. 601.10 respectively. The current market cap of the company is Rs. 3447.22 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 71.11%, while Institutions and Non-Institutions held 17.24% and 11.65% respectively.</p><p style="text-align: justify;">Thyrocare Technologies has completed the acquisition by way purchase of 100% equity shares in Think Health Diagnostic (Think Health) from all the existing shareholders of Think Health on February 27, 2024 and consequently Think Health has become wholly-owned subsidiary company of Thyrocare with effective from February 27, 2024.</p><p style="text-align: justify;">Thyrocare Technologies is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries.</p><div style="text-align: justify;"><br></div> |
| 28-Feb-2024 | Torrent Power, Infosys and UGRO Capital to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">Torrent Power </span>has emerged as the Successful Bidder and has received Letter of Intent from PFC Consulting on February 27, 2024 for Establishment of Inter-state transmission scheme ‘Transmission System for Evacuation of Power from RE Projects in Solapur (1,500 MW) SEZ in Maharashtra' under Tariff Based Competitive Bidding (TBCB) Process.</p><p style="text-align: justify;"><span style="font-weight: bold;">Infosys </span>has launched its Responsible AI Suite, a part of Infosys Topaz, an AI-first set of services, solutions and platforms using generative AI. The rise of powerful generative AI systems in the past year has raised several concerns and conversations around the ethical dimensions of AI. According to the Infosys Generative AI Radar, by Infosys Knowledge Institute, enterprises worldwide are identifying data privacy, security, ethics, and bias as the primary challenges in their pursuit of innovation with AI. The Responsible AI Suite is designed to help enterprises balance innovation with ethical considerations, such bias and privacy prevention, and maximize their return on investments.</p><p style="text-align: justify;"><span style="font-weight: bold;">UGRO Capital </span>has raised Rs 200 crore through the allotment of 20,00,000 Secured, Rated, Listed, Redeemable, Non-Convertible Debentures (NCDs) having face value of Rs 1,000 each at par through public issue. The Investment and Borrowing Committee of the Board of Directors of the Company (Committee) on February 27, 2024 has inter alia made an allotment of the same. </p><p style="text-align: justify;"><span style="font-weight: bold;">Hindustan Zinc </span>has incorporated a wholly owned subsidiary (WOS) of the Company in the name of ‘Hindmetal Exploration Services'. The said WOS has been incorporated with object to explore, discover, develop and tap mineral resources including strategic minerals, deep-seated minerals and offshore minerals through systematic exploration of all types of mineral deposits and to participate in the auctioning of mining blocks containing critical minerals.</p><p style="text-align: justify;"><span style="font-weight: bold;">Titan Company </span>is all set to purchase balance 1,19,489 equity shares held by the individual shareholders of CaratLane Trading (CaratLane) representing 0.36% of the total paid-up equity share capital of face value of Rs 2 each of CaratLane. The purchase transaction would be completed on fulfilment of other closing conditions. The Company currently holds 99.64% of the total equity share capital of CaratLane. The proposed purchase of shares would further increase the Company's stake in CaratLane to 100%, thereby making CaratLane a Wholly Owned Subsidiary of the Company. The indicative time period for completion of the transaction would be March 31, 2024.</p><p style="text-align: justify;"><span style="font-weight: bold;">Thyrocare Technologies </span>has completed the acquisition by way purchase of 100% equity shares from all the existing shareholders of Think Health Diagnostic on February 27, 2024 and consequently Think Health has become wholly-owned subsidiary company of Thyrocare with effect from February 27, 2024.</p><p style="text-align: justify;"><span style="font-weight: bold;">Bn Holdings</span> has incorporated a wholly owned subsidiary (WOS) in London, England. This WOS is a private company limited by shares and named as ‘BN Holdings Europe'. The said WOS has been incorporated with an object of Manufacture of other food products n.e.c, Other manufacturing n.e.c., Manufacture of oils and fats, Wholesale of dairy products, eggs and edible oils and fats.</p> |
| 23-Feb-2024 | Thyrocare Technologies informs about appointment of chief commercial officer | <p style="text-align: justify;">Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations'), Thyrocare Technologies has informed that, Nitin Chugh has been appointed as Chief Commercial Officer of the Company, being part of the Senior Management of the Company with effect from February 22, 2024. Further, the details/disclosures required under Regulation 30 of the SEBI Listing Regulations, read the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure -A.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 01-Feb-2024 | Thyrocare Technologies to acquire 100% stake in Think Health | <p style="text-align: justify;">Thyrocare Technologies has entered into a Share Purchase Agreement with Think Health Diagnostic (Think Health) and their existing shareholders on February 1, 2024 to acquire 100% stake in Think Health by way purchase of equity shares from all the existing shareholders of Think Health. With this acquisition, the Company aims to enter into a new line of business of offering ECG testing services at home.</p><p style="text-align: justify;">Thyrocare Technologies is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries.</p><div style="text-align: justify;"><br></div> |
| 31-Oct-2023 | Thyrocare Technologies informs about outcome of board meeting | <div style="text-align: justify;">Thyrocare Technologies has informed that the Board, at its meeting held today, October 31, 2023, considered and approved the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2023. Pursuant to Regulation 33(3) of the SEBI Listing Regulations, copies of the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2023, along with the Limited Review Reports on said financial results issued by the Statutory Auditors of the Company are attached. The said financial results are also being made available on the Company's website at www.thyrocare.com and the extract is being published in one English and one Marathi newspaper.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 20-Sep-2023 | Thyrocare Technologies enters into Subscription Agreement with Kastipharm | <p style="text-align: justify;">Thyrocare Technologies has entered into a Subscription Agreement at Tanzania with Kastipharm and other individuals on September 19, 2023 for setting up a joint venture company for the purpose of providing diagnostic and healthcare services to customers directly, through the laboratories that will be owned and operated by joint venture company or through third party laboratories in Tanzania. The JV company is incorporated as a part of long term business plans of the company on expansion of company's existing business of providing diagnostics services in different geographies.</p><p style="text-align: justify;">Thyrocare Technologies is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries.</p><div style="text-align: justify;"><br></div> |
| 22-Jun-2023 | Thyrocare Technologies informs about disclosure | <p style="text-align: justify;">Thyrocare Technologies has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Arisaig Asia Fund F K A Arisaig Asia Consumer Fund.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 08-Jun-2023 | Thyrocare Technologies informs about disclosure | <p style="text-align: justify;">Thyrocare Technologies has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon Life India Trustee.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 17-May-2023 | Thyrocare Technologies informs about conference call | <p style="text-align: justify;">Pursuant to Regulation 30 of SEBI Listing Regulations, Thyrocare Technologies has informed that a conference call for the analysts/investors is arranged by its management to discuss the Company's financial results for quarter / financial year ended March 31, 2023, on Tuesday, May 23, 2023 at 6 pm. (IST). The financial results of the Company for quarter / financial year ended March 31, 2023 will be announced on the same date May 23, 2023.</p><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
